Clinical trial NCT00840190: A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
Official title: An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Hematologic Malignancy
Lead sponsor: Piramal Enterprises Limited
Sponsor class: INDUSTRY
First posted: 2009-02-10
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I open label study to evaluate safety and efficacy of P1446A-05 in subjects with advanced refractory malignancies. Subjects of solid tumors or hematologic malignancies will be included. This is a dose escalation study following an accelerated titration design. It is expected that around 50 subjects would be enrolled in the study.Safety assessment will be conducted on the basis of vital signs, physical examination and laboratory investigations undertaken at regular intervals as per the schedule.

Detailed description: This is a phase I open label study to evaluate safety and efficacy of P1446A-05 in subjects with advanced refractory malignancies. Subjects of solid tumors or hematologic malignancies will be included as per selection criteria. Starting dose for P1446A-05 in this study is 75 mg orally once daily for 14 days followed by 7 days rest. This constitutes one cycle for P1446A-05.Three patients will be enrolled in first cohort at this starting dose of P1446A-05. If this dose is well tolerated then dose escalation will be undertaken for subsequent cohorts as per accelerated titration design as described in protocol till maximum tolerated dose(MTD) for P1446A-05 is determined. The MTD will be the recommended phase 2 dose. 10 additional patients might be enrolled at this MTD to further evaluate safety and efficacy. It is expected that around 50 subjects would be enrolled in the study.Safety assessment will be conducted on the basis of vital signs, physical examination and laboratory investigations undertaken at regular intervals as per the schedule.

Eligibility criteria: Inclusion Criteria:

1. Subjects must have histologically and/ or cytologically confirmed solid malignant tumor or hematologic malignancy that is refractory to currently available treatment or for which no standard treatment exists
2. Subjects of either sex and more than or equal to 18 years of age
3. ECOG (Eastern Cooperative Oncology Group) performance status less than or equal to 2
4. Subjects with life expectancy of at least 4 months
5. Hemoglobin greater than or equal to 8 g/dl
6. Absolute neutrophil count greater than or equal to 1000/mm3
7. Platelet count greater than or equal to 50,000/ mm3
8. Total bilirubin less than or equal to 1.5 X institutional upper limit of normal (ULN)
9. AST/ALT less than or equal to 3 X institutional upper limit of normal (ULN)
10. Creatinine less than or equal to 1.5 X institutional upper limit of normal (ULN)
11. Ability to understand and willingness to sign a written informed consent document.

Exclusion criteria

1. Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 4 weeks prior to day 1 of study drug administration (6 weeks for nitrosoureas or mitomycin C) or have not recovered completely from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents
2. Subjects who have received autologous or allogeneic bone marrow transplant within 6 months of day 1 of study drug administration
3. Subjects with known brain metastases at the time of screening
4. Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to day 1 of study drug administration or who have not completely recovered from adverse effects of the investigational agent received prior to this period.
5. History of allergic reactions attributed to compounds of similar chemical structure to P1446A-05.
6. Subjects on immunosuppressive therapy.
7. History of unstable angina or myocardial infarction or stroke within previous 6 months.
8. Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
9. Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B.
10. History of any other prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been diseasefree for at least 3 years.
11. Women who are pregnant or lactating.
12. Women of childbearing potential \[defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months)\] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the informed consent document), during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilised.
13. Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study.

Primary outcomes:
measure: To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of P1446A-05 in subjects with advanced refractory malignancies
timeFrame: End of cycle 1 (3 weeks)
Secondary outcomes:
measure: 1 To evaluate safety and tolerability ,pharmacokinetics of P1446A-05 in study population 2. To evaluate efficacy of P1446A-05 3. To perform exploratory analysis of biomarkers associated with use of P1446A-05 in the study population
timeFrame: End of cycle 1 (3 weeks)
Other outcomes:
Locations:
city: Mumbai
country: India
facility: Tata Memorial Centre
state: Maharashtra
city: Pune
country: India
facility: Ruby Hall Clinic
state: Maharashtra
city: Pune
country: India
facility: Jehangir Hospital
state: Maharashtra
city: Jaipur
country: India
facility: SEAROC Cancer Centre,
state: Rajasthan
city: Jaipur
country: India
facility: Bhagwan Mahaveer Cancer Hospital
state: Rajasthan
Study officials:
affiliation: Consultant
name: Minish Jain, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Sr. Hemato-Oncologist & Pediatric Oncologist
name: Naresh Somani, D.M.
role: PRINCIPAL_INVESTIGATOR
affiliation: Senior Consultant and Director
name: Anish Maru, D.M.
role: PRINCIPAL_INVESTIGATOR
affiliation: Consultant Medical Oncologist
name: Shona Nag, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Oncology Associate Professor
name: Sudeep Gupta, D.M.
role: PRINCIPAL_INVESTIGATOR
References: